---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-003208"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2025-01-14T23:59:59+00:00"
generated_at: "2026-05-28T01:45:19.324625+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cellectar reports iopofosine 83.6% ORR in WM; plans confirmatory study for accelerated approval

## Summary
- Iopofosine I 131 achieved 83.6% ORR and 58.2% MRR in Phase 2 CLOVER-WaM for Waldenstrom's Macroglobulinemia; primary endpoint of 20% MRR exceeded.
- Company expects confirmatory randomized study (40-60 patients/arm) with FDA alignment in H1 2025; cash runway through Q4 2025.
- Advancing alpha-emitting PRC CLR 121225 into Phase 1/2a solid tumor studies; IND filing expected Q1 2025.
- Auger-emitting PRC CLR 121125 IND cleared; Phase 1b/2a dose finding study in triple-negative breast cancer planned.
- Company pursuing partnerships for iopofosine; presentation at Biotech Showcase on Jan 14, 2025.

## SEC filing metadata
- accession: 0001104659-25-003208
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2025-01-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465925003208/0001104659-25-003208-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465925003208/tm253236d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-003208
- JSON: https://secwatch.observer/filing/0001104659-25-003208.json
- Plain text: https://secwatch.observer/filing/0001104659-25-003208.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.